
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Ophthalmic Goods · market cap $1.3B · as of 2026-07-03
Research and calibrated estimates, not financial advice — verify before acting.
| Asset | Phase | Indication |
|---|---|---|
| Inactivated SARS-CoV-2 Vaccine (Vero cell) | Phase 3 | COVID-19 |
| Diphtheria,Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed | Phase 3 | Whooping Cough |
| SARS-CoV-2 Vaccine (Vero Cell), Inactivated | Phase 3 | COVID-19 Pneumonia |
Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
See ProApproval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.